Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Resolution of fever -51% Improvement Relative Risk Time to viral- 58% Li et al. Paxlovid for COVID-19 EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 20 patients in China (December 2022 - January 2023) Worse recovery (p=0.008) and faster viral clearance (p=0.033) Li et al., Frontiers in Pediatrics, doi:10.3389/fped.2023.1160929 Favors paxlovid Favors control
Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
Li et al., Frontiers in Pediatrics, doi:10.3389/fped.2023.1160929
Li et al., Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron.., Frontiers in Pediatrics, doi:10.3389/fped.2023.1160929
Apr 2023   Source   PDF  
  All Studies   Meta
Retrospective 20 pediatric hematological disease patients in China, showing faster viral clearance with paxlovid, but slower resolution of fever.
Confounding by contraindication. [Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
resolution of fever, 51.3% higher, relative time 1.51, p = 0.008, treatment 9, control 11.
time to viral-, 57.6% lower, relative time 0.42, p = 0.03, treatment 9, control 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 25 Apr 2023, retrospective, China, peer-reviewed, 9 authors, study period 10 December, 2022 - 20 January, 2023.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: | EDITED BY Joanna Zawitkowska, Medical University of Lublin, Poland REVIEWED BY Desiree Caselli, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Italy Agnieszka Mizia-Malarz, Medical University of Silesia, Poland *CORRESPONDENCE Chun Chen Hongman Xue Yucai Cheng † These authors have contributed equally to this work SPECIALTY SECTION This article was submitted to Pediatric Hematology and Hematological Malignancies, a section of the journal Frontiers in Pediatrics RECEIVED 07 February 2023 ACCEPTED 23 March 2023 PUBLISHED 25 April 2023 CITATION Li Y, Liu Y, Wen L, Chen H, Wang W, Tian M, Cheng Y, Xue H and Chen C (2023) Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant. Front. Pediatr. 11:1160929. doi: 10.3389/fped.2023.1160929 COPYRIGHT © 2023 Li, Liu, Wen, Chen, Wang, Tian, Cheng, Xue and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Original Research PUBLISHED 25 April 2023 DOI 10.3389/fped.2023.1160929 Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant Yixian Li1†, Yong Liu1†, Luping Wen2, Hui Chen3, Wenqing Wang1, Mengyao Tian1, Yucai Cheng1*, Hongman Xue1* and Chun Chen1* 1 Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China, 2Department of Pharmacy, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China, 3Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China Objective: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. Methods: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological diseases diagnosed with novel coronavirus infection in the outpatient and emergency department of the Seventh Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. Results: According to whether to give paxlovid or not, it is divided into group A (paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6 days in group A and 0–3 days in group B. The viral clearance time was shorter in group A than in group B. The inflammatory indexes CRP and PCT were significantly higher in group A than in group B (P < 0.05). Twenty patients were followed up for 1 month after leaving the hospital, and there were 5 cases of reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1 case of loss of appetite within 2 weeks. Conclusions: Paxlovid has no apparent adverse reactions in children 12 years old and younger with underlying hematological diseases infected with the new coronavirus. Focusing on the interaction between paxlovid and other drugs is necessary during the treatment. KEYWORDS clinical efficacy, PAXLOVID,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop